AP2377A - Benzimidazole derivatives. - Google Patents

Benzimidazole derivatives.

Info

Publication number
AP2377A
AP2377A AP2009005089A AP2009005089A AP2377A AP 2377 A AP2377 A AP 2377A AP 2009005089 A AP2009005089 A AP 2009005089A AP 2009005089 A AP2009005089 A AP 2009005089A AP 2377 A AP2377 A AP 2377A
Authority
AP
ARIPO
Prior art keywords
benzimidazole derivatives
benzimidazole
derivatives
Prior art date
Application number
AP2009005089A
Other languages
English (en)
Other versions
AP2009005089A0 (en
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2009005089A0 publication Critical patent/AP2009005089A0/en
Application granted granted Critical
Publication of AP2377A publication Critical patent/AP2377A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2009005089A 2007-06-29 2008-06-16 Benzimidazole derivatives. AP2377A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (fr) 2007-06-29 2008-06-16 Dérivés de benzamidazole

Publications (2)

Publication Number Publication Date
AP2009005089A0 AP2009005089A0 (en) 2009-12-31
AP2377A true AP2377A (en) 2012-03-07

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009005089A AP2377A (en) 2007-06-29 2008-06-16 Benzimidazole derivatives.

Country Status (45)

Country Link
US (2) US8148401B2 (fr)
EP (1) EP2170860B9 (fr)
JP (2) JP4567099B2 (fr)
KR (1) KR101143246B1 (fr)
CN (1) CN101687841B (fr)
AP (1) AP2377A (fr)
AR (1) AR067346A1 (fr)
AU (1) AU2008272641B2 (fr)
BR (1) BRPI0813412B8 (fr)
CA (1) CA2690953C (fr)
CL (1) CL2008001922A1 (fr)
CO (1) CO6160232A2 (fr)
CR (1) CR11150A (fr)
CU (1) CU23847B1 (fr)
CY (2) CY1118650T1 (fr)
DK (1) DK2170860T5 (fr)
DO (1) DOP2009000278A (fr)
EA (1) EA016888B1 (fr)
EC (1) ECSP099803A (fr)
ES (1) ES2609258T3 (fr)
FR (1) FR20C1038I2 (fr)
GE (1) GEP20125702B (fr)
GT (1) GT200900328A (fr)
HN (1) HN2008000974A (fr)
HR (1) HRP20161562T2 (fr)
HU (2) HUE030052T4 (fr)
IL (1) IL202420A (fr)
LT (2) LT2170860T (fr)
MA (1) MA31466B1 (fr)
ME (1) ME00962B (fr)
MY (1) MY148636A (fr)
NI (1) NI200900219A (fr)
NL (1) NL301057I2 (fr)
NO (1) NO2020027I1 (fr)
NZ (1) NZ581889A (fr)
PA (1) PA8785401A1 (fr)
PE (2) PE20090772A1 (fr)
PL (1) PL2170860T3 (fr)
PT (1) PT2170860T (fr)
RS (1) RS55395B9 (fr)
SI (1) SI2170860T1 (fr)
TN (1) TN2009000544A1 (fr)
TW (1) TWI371451B (fr)
UY (1) UY31164A1 (fr)
WO (1) WO2009004427A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20125702B (en) * 2007-06-29 2012-12-10 Pfizer Benzimidazole derivatives
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
KR20120078703A (ko) 2009-08-26 2012-07-10 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 고리 유도체 및 이의 용도
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
CA2813162C (fr) 2010-10-20 2015-06-16 Pfizer Inc. Derives de pyridine-2 en tant que modulateurs des recepteurs smoothened
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Nttドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2684167B1 (fr) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utiles dans le traitement de maladies
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
CA2849820C (fr) * 2011-09-26 2019-08-27 Merck Patent Gmbh Composes de benzylpiperidine utilises comme antagonistes des recepteurs a l'acide lysophosphatidique (lpa)
WO2013192423A2 (fr) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles pour traiter les maladies impliquant des protéines de la famille bcl-2 avec des dérivés de quinoline
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
EP2996689A1 (fr) 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ, インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
SG11201707863QA (en) * 2015-04-24 2017-11-29 Pfizer Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP7792189B2 (ja) * 2019-03-29 2025-12-25 デクセリアルズ株式会社 接着剤組成物
HRP20240302T1 (hr) 2020-01-28 2024-05-10 Assia Chemical Industries Ltd Postupci za pripremu glasdegiba i njegove soli i krutih oblika glasdegib maleata i postupak za njihovu pripremu
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
WO2021191278A1 (fr) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Forme dimaléate de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridine -4-yl)-3-(4-cyanophényl)urée
WO2021261601A1 (fr) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Méthode de sélection d'un patient cancéreux pour lequel une polythérapie d'un rétinoïde et d'un agent de traitement du cancer sera efficace, et médicament combiné d'un rétinoïde et d'un agent de traitement du cancer
WO2023002362A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Traitement d'une malignité hématologique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048154A1 (fr) * 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd Nouveaux derives de quinoleines
WO2006050506A1 (fr) * 2004-11-03 2006-05-11 Curis, Inc. Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci
WO2006124780A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0211513A (pt) 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
PL377215A1 (pl) * 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
WO2005042495A1 (fr) 2003-10-21 2005-05-12 Imclone Systems Incorporated Composes de (benzimidazol-2-yl)-phenyl-phenyl-uree et procedes d'inhibition de l'activite de l'heparanase
AU2004285053B2 (en) 2003-10-28 2010-10-21 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
DE102005012875B4 (de) * 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2008064830A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
CA2672815A1 (fr) 2006-12-15 2008-06-26 Pfizer Products Inc. Derives du benzamidazole
GEP20125702B (en) 2007-06-29 2012-12-10 Pfizer Benzimidazole derivatives
EP2303275A4 (fr) 2008-06-17 2012-05-09 Univ Duke Modulateurs du récepteur smoothened
JP5555236B2 (ja) 2008-08-25 2014-07-23 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーター

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048154A1 (fr) * 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd Nouveaux derives de quinoleines
WO2006050506A1 (fr) * 2004-11-03 2006-05-11 Curis, Inc. Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci
WO2006124780A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase

Also Published As

Publication number Publication date
JP2010531869A (ja) 2010-09-30
LTPA2020528I1 (lt) 2020-09-25
DK2170860T5 (en) 2017-03-20
CO6160232A2 (es) 2010-05-20
TWI371451B (en) 2012-09-01
ME00962B (fr) 2012-06-20
IL202420A (en) 2014-05-28
LT2170860T (lt) 2017-01-10
EP2170860B1 (fr) 2016-11-02
AU2008272641A1 (en) 2009-01-08
US8148401B2 (en) 2012-04-03
EA016888B1 (ru) 2012-08-30
SI2170860T1 (sl) 2017-01-31
BRPI0813412A2 (pt) 2014-12-30
CR11150A (es) 2010-02-08
HRP20161562T2 (hr) 2017-04-21
AU2008272641B2 (en) 2013-08-29
EP2170860A2 (fr) 2010-04-07
CA2690953A1 (fr) 2009-01-08
EP2170860B9 (fr) 2017-02-22
NO2020027I1 (no) 2020-08-11
US20120157495A1 (en) 2012-06-21
NZ581889A (en) 2011-05-27
HUS2000031I1 (hu) 2020-09-28
CY1118650T1 (el) 2017-07-12
CN101687841B (zh) 2013-07-10
CN101687841A (zh) 2010-03-31
RS55395B9 (sr) 2020-01-31
PE20121010A1 (es) 2012-08-06
KR20100028120A (ko) 2010-03-11
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
US8431597B2 (en) 2013-04-30
UY31164A1 (es) 2009-01-30
JP4567099B2 (ja) 2010-10-20
IL202420A0 (en) 2010-06-30
CA2690953C (fr) 2012-10-02
JP2010280693A (ja) 2010-12-16
CU23847B1 (es) 2012-10-15
HUE030052T4 (en) 2017-06-28
TW200911792A (en) 2009-03-16
CU20090225A7 (es) 2012-02-15
BRPI0813412B1 (pt) 2020-01-21
CY2020028I1 (el) 2020-11-25
NL301057I2 (nl) 2020-09-10
HRP20161562T1 (hr) 2016-12-30
AP2009005089A0 (en) 2009-12-31
TN2009000544A1 (fr) 2011-03-31
WO2009004427A2 (fr) 2009-01-08
GT200900328A (es) 2011-08-29
MY148636A (en) 2013-05-15
DOP2009000278A (es) 2009-12-31
WO2009004427A3 (fr) 2009-06-04
AR067346A1 (es) 2009-10-07
ES2609258T3 (es) 2017-04-19
RS55395B1 (sr) 2017-04-28
FR20C1038I2 (fr) 2021-08-13
LTC2170860I2 (lt) 2022-03-10
HN2008000974A (es) 2011-01-24
PT2170860T (pt) 2017-01-04
KR101143246B1 (ko) 2012-05-18
PL2170860T3 (pl) 2017-05-31
CL2008001922A1 (es) 2009-01-02
HUE030052T2 (hu) 2017-04-28
EA200971104A1 (ru) 2010-06-30
CY2020028I2 (el) 2020-11-25
NL301057I1 (nl) 2020-07-22
FR20C1038I1 (fr) 2020-10-02
US20090005416A1 (en) 2009-01-01
MA31466B1 (fr) 2010-06-01
GEP20125702B (en) 2012-12-10
PA8785401A1 (es) 2009-01-23
DK2170860T3 (en) 2017-01-09
HK1139658A1 (en) 2010-09-24
ECSP099803A (es) 2010-01-29
BRPI0813412B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HUS2000031I1 (hu) Benzimidazol-származékok
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
IL205759A0 (en) Isoxazolo-pyridine derivatives
IL205753A0 (en) Isoxazolo-pyridazine derivatives
IL202020A0 (en) Spiroindolinone derivatives
ZA201001058B (en) Quinazolinamide derivatives
IL202830A0 (en) Indazolamide derivatives
IL205755A0 (en) Isoxazolo-pyrazine derivatives
IL204683A0 (en) Imidazole derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
AP2010005345A0 (en) Indazole derivatives.
IL209733A0 (en) New benzimidazole derivatives
IL202667A0 (en) Isoxazole-imidazole derivatives
IL193475A0 (en) Benzimidazole derivatives
PL2245028T3 (pl) Pochodne 5-aminocyklilometyloksazolidyn-2-onu
EP2133347A4 (fr) Dérivés de 1-biarylazétidinone
EP2172454A4 (fr) Dérivé de benzimidazole
IL202463A0 (en) Sulfonyl-quinoline derivatives
IL202159A0 (en) Piperidine-amide derivatives
IL211806A0 (en) New benzimidazole derivatives
ZA201002218B (en) Thiadiazinone derivatives
ZA200908626B (en) Benzimidazole Derivatives
GB0702266D0 (en) 7-Azaindoe derivatives
ZA201000311B (en) Sulfonyl-quinoline derivatives
AP2009005065A0 (en) Sulfonyl-quinoline derivatives